BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

SOLEXA ANNOUNCES THIRD QUARTER 2006 FINANCIAL RESULTS CONFERENCE CALL ON NOVEMBER 14

HAYWARD, Calif. (November 8, 2006) – Solexa, Inc. (NASDAQ: SLXA) today announced that it will release financial results for the third quarter of 2006 after market close on Tuesday, November 14, 2006. Solexa management will host an investment-community conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss those results and answer questions.

Individuals interested in participating in the conference call may do so by dialing (800) 366-7417 for domestic callers or (303) 262-2139 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investors section of the Company's Web site at www.solexa.com .

A webcast replay will be available on the Solexa Web site. A telephone replay will be available for 48 hours following the conclusion of the call by dialing (800) 405-2236 for domestic callers, or (303) 590-3000 for international callers, and entering pass code 11073357#.

- ENDS -

About Solexa


Solexa, Inc. is developing and commercializing the Solexa Genome Analysis System, which will be used to perform a range of analyses including whole genome resequencing, gene expression analysis and small RNA analysis. Solexa expects its first-generation instrument, the 1G Genome Analyzer, to generate over a billion bases of DNA sequence per run and to enable human genome resequencing below $100,000 per sample, making it the first platform to reach this important milestone. Solexa's longer-term goal is to reduce the cost of human re-sequencing to a few thousand dollars for use in a wide range of applications from basic research through clinical diagnostics. For further information, please visit www.solexa.com .

This press release contains "forward-looking" statements, including statements related to the current views of Solexa management as to future products, product development, the commercial introduction of the Company's novel genetic analysis technology and the expansion and success of Solexa's commercial application of its genomics technologies. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "predicts," "expects," "envisions," "hopes," "estimates," "intends," "will," "continue," "may," "potential," "should," "confident," "could" and similar expressions are intended to identify forward-looking statements. There can be no assurance that such expectations of any of the forward-looking statements will prove to be correct, and actual results could differ materially from those projected or assumed in the forward-looking statements. There are a number of important factors that could cause the results of Solexa to differ materially from those indicated by these forward-looking statements including, among others, risks detailed from time to time in the Company's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2005 and its Form 10-Q for the quarter ended June 30, 2006. Solexa does not undertake any obligation to update forward-looking statements.

For more information, please contact:

European Media Contact:

Northbank Communications
Sue Charles, CEO s.charles@northbankcommunications.com 
Lorna Watson, Account Director l.watson@northbankcommunications.com
+44 (0)20 3008 7550

Investor Contacts:

EVC Group, Inc.
Doug Sherk
415-896-6818
dsherk@evcgroup.com

Jenifer Kirtland
415-896-2005
jkirtland@evcgroup.com

North American Media Contact:

EVC Group, Inc.
Steve DiMattia
646-277-8706
sdimattia@evcgroup.com

  Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreements

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.